The results of this trial indicate that dapagliflozin is superior to placebo in improving glycemic control and noninferior but not superior for reducing mace in patients with dm2 and high cv risk. However, few diabetes mellitus trials have prospectively evaluated and adjudicated heart failure as an end point. Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction. Other ongoing studies of other incretinbased therapies will further clarify whether this was a chance observation or a true side effect. We randomized 16 492 patients with type 2 diabetes t2d to saxagliptin or placebo, added to current antidiabetic medications, and followed them for. Timi 53 cv outcomes trial summary saxagliptin and cardiovascular cv outcomes in patients with type 2 diabetes mellitus. Savor timi 53 steering committee and investigators. Thrombolysis in myocardial infarction 53 savortimi 53 trial. Saxagliptin and cardiovascular outcomes in patients with.
Study design and oversight as described previously,19 the savortimi 53 trial was a multicenter, randomized, doubleblind, placebocontrolled trial that randomized 16492 patients at 788 sites in 26 countries from may 2010 to december 2011 with type 2 dm, hemoglobin a1c between 6. To study the effects of saxagliptin, a dipeptidyl peptidase. The patients in the trial all had type 2 diabetes and either had cardiovascular disease or were at high risk for it. Download slide set pdf plasma ceramide and phospholipid based risk score in patients after acs gencer, aha 2019. Incidence of pancreatitis and pancreatic cancer in a. We investigated the effect of saxagliptin in the savortimi 53 trial according to baseline renal function. Effect of saxagliptin on renal outcomes in the savor timi.
Bhatt, md, mph on behalf of the savortimi 53 steering committee and investigators european society of cardiology, amsterdam september 2, 20. Savortimi 53 was a randomized, doubleblind, placebocontrolled trial that involved 16,500 patients in 25 countries with type 2 diabetes who had a history of established cardiovascular disease or multiple risk factors, with or without renal impairment. A total of 16 492 patients with type 2 diabetes mellitus and a history of, or at risk of, cardiovascular events were randomized to saxagliptin or placebo mean followup, 2. Operational and scientific lessons from the savor timi53. Effect of saxagliptin on renal outcomes in the savor timi 53 study appendixes. The results of the savortimi 53 trial indicate that saxagliptin, a dpp4 inhibitor, is not associated with an excess of cv events as compared with placebo in patients with dm2 and either established cv disease or risk factors. Results of savortimi 53 interview with benjamin scirica, md, mph, assistant professor of medicine, harvard medical school, boston, ma a large trial of the dipeptidyl peptidase4 dpp4 inhibitor saxagliptin examined cardiovascular safety. On behalf of the savortimi 53 steering committee and investigators. Savortimi 53 is a randomized, doubleblind, placebocontrolled trial to assess the cardiovascular efficacy and safety of saxaglipitin, a dpp4 inhibitor, when added to standard of care in patients with type 2 diabetes mellitus. European society of cardiology, amsterdam september 2, 20. There was a reduction in hf hospitalizations, and also a salutary effect on renal outcomes. Pdf effect of saxagliptin on renal outcomes in the savor. A total of 16 492 patients with type 2 diabetes mellitus and a history of, or at.
Saxagliptin and cardiac structure and function full text. The savor timi 53 trial supports the overall cv safety of saxagliptin in a robust number of elderly and very elderly participants, although the risk of heart failure hospitalization was increased irrespective of age category. Frequency of cancer events with saxagliptin in the savortimi. This trial, named savortimi 53, found a 27% increase in the rate of firstevent hospitalization for heart failure among its saxagliptintreated subjects when compared to placebotreated subjects. As described previously, the savortimi 53 trial was a multicenter. The savortimi 53 randomized trial of 16,492 8,212 on placebo. Savortimi 53 evaluated drug intervention saxagliptin onglyza vs. Savor timi 53, a multicenter, randomized, doubleblind, placebocontrolled phase 4 trial conducted at 788 sites in 26 countries, included patients with type 2 diabetes mellitus, hba1c levels between 6. Cardiovascular outcomes of patients in savortimi 53 by. Cardiovascular outcomes of patients in savortimi 53 by baseline. Savortimi 53 sets new standard for cardiovascular outcome. Heart failure, saxagliptin, and diabetes mellitus aha journals.
Pdf saxagliptin and heart failure in the savortimi 53. Saxagliptin and heart failure in the savortimi 53 trial. European society of cardiology,amsterdam september 2, 20. Rxfiles trial summary oct 20 kellie towriss bsp, hosp pharm resident. Timi 53 cv outcomes trial summary saxagliptin and cardiovascular cv outcomes in patients with type 2 diabetes mellitus savor. The safety of dipeptidyl peptidase 4 inhibitors and the risk for heart failure. Research design and methods savortimi 53 was a multicenter, ran. Timi 53 trial was a cardiovascular outcome trial designed to assess the cardiovascular safety of saxagliptin vs placebo added to standard care.
Since its inception in 1984, the timi study group has been an academic research organization dedicated to advancing the knowledge and care of patients suffering from cardiovascular disease and its. Udell ja1, bhatt dl2, braunwald e2, cavender ma2, mosenzon o3. Deepak bhatt, md, mph professor of medicine, harvard medical school chief of cardiology, va boston healthcare system director, integrated interventional cardiovascular program, brigham and women. Astrazeneca and bristolmyers squibb announce top line. Letter by muskiet et al regarding article, heart failure. Saxagliptin assessment of vascular outcomes recorded in. Further studies are needed to completely resolve the pancreatic safety issues with incretinbased therapy. Efficacy and safety of saxagliptin in older participants. Reflections on the bradford hill criteria find, read and cite all the. Oct 22, 20 deepak bhatt, md, mph professor of medicine, harvard medical school chief of cardiology, va boston healthcare system director, integrated interventional cardiovascular program, brigham and women.
Savor timi 53 demonstrated noninferiority for major cardiovascular events cardiovascular death, myocardial infarction, stroke but not superiority. In this post hoc analysis, patients in savortimi 53 saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus with baseline biomarker samples n12 156 were classified as ever versus never taking metformin during the trial period. Pdf incidence of fractures in patients with type 2. Effect of saxagliptin on renal outcomes in the savortimi 53. Number and % of patients at the saxagliptin and placebo arms, according to egfr and on treatment acr groups at baseline, 1 year, and eot n % from acr by treatment arm egfr50 mlminbsa acr 300 mgg mgg. Research design and methods we studied renal outcomes of 16,492 patients with type 2 diabetes, randomized to saxagliptin versus placebo and followed for a median of 2. In the trial as a whole, saxagliptin had no detectable effect on cv events, improved glycemic control, and reduced the development and progression of albuminuria. In this analysis from the savortimi 53 trial comparing cardiovascular outcomes among patients with t2dm and high cardiovascular risk, metformin use was associated with a lower rate of allcause mortality, even after adjustment for clinical variables and biomarkers, but was not associated with lower rates of the composite end point of.
Solidtimi 52 is a randomized, doubleblind, placebocontrolled trial to assess the efficacy of darapladib, a novel lppla2 inhibitor, when added to standard of care in highrisk patients stabilized after acs. Savor timi 53 was a multicenter, randomized, doubleblind, placebocontrolled, phase 4 trial. Effect of saxagliptin on renal outcomes in the savortimi. Research design and methods study design and patient population savortimi 53 was a multicenter, randomized,doubleblind,placebocontrolled trial that randomized 16,492 patients at 788 sites in 26 countries. The savortimi 53 trial supports the overall cv safety of saxagliptin in a robust number of elderly and very elderly participants, although the risk of heart failure hospitalization was increased irrespective of age category. Scirica bm, braunwald e, raz i, cavender ma, morrow da, jarolim p, udell ja, mosenzon o, im k, umezeronini aa, pollack ps, hirshberg b, frederich r, lewis bs, mcguire dk, davidson j, steg pg, bhatt dl. Operational and scientific lessons from the savor timi53 trial. The investigators in the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus savorthrombolysis in myocardial infarction timi 53 study are listed in the. Thrombolysis in myocardial infarction 53 savor timi 53 trial randomized 16,492 type 2 diabetic patients with high cv risk and varying degrees of renal function and albuminuria to treatment with the dpp4 inhibitor saxagliptin or placebo and followed them prospectively for a median of 2. Savortimi 53 was the first fdamandated cardiovascular outcome trial to be presented and published. Cardiovascular outcomes according to urinary albumin and. We conducted the trial at 788 sites in 26 countries see the supplementary appendix. It compared saxagliptin and placebo in 16,492 patients with type 2 diabetes. Harvard heart letter, duke clinical research institute clinical trial steering committees.
The net effect is a reduction in glucagon level and increased insulin secretion. Saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus savor timi 53. Jun 19, 20 savor timi 53 was a randomized, doubleblind, placebocontrolled trial that involved 16,500 patients in 25 countries with type 2 diabetes who had a history of established cardiovascular disease or multiple risk factors, with or without renal impairment. Diabetes mellitus and heart failure frequently coexist. Atlas acs 2timi 51 was a phase iii, multicenter, randomized, doubleblind, placebocontrolled clinical trial evaluating an oral, direct factor xa inhibitor rivaroxaban in subjects following an acute coronary syndrome.
Savortimi 53 was a multicenter, randomized, doubleblind, placebocontrolled, phase 4 trial. The savor timi 53 randomized trial of 16,492 8,212 on placebo. Observations from the savor timi 53 randomized trial. Savor timi 53 was the first fdamandated cardiovascular outcome trial to be presented and published. Thrombolysis in myocardial infarction 53 savortimi 53 trial randomized 16,492 type 2 diabetic patients with high cv risk and varying degrees of renal function and albuminuria to treatment with the dpp4 inhibitor saxagliptin or placebo and followed them prospectively for a median of 2. Savortimi 53 is a randomized, doubleblind, placebocontrolled trial to assess the cardiovascular efficacy and safety of saxaglipitin, a dpp4 inhibitor, when.
Thus, we analyzed the savortimi 53 trial to compare the cardiovascular effects of saxagliptin vs placebo according to baseline hba1c. Saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus savor timi 53 deepak l. The savor timi 53 trial supports the overall cv safety of saxagliptin in a robust number of elderly and very elderly participants, although the risk of heart failure hospitalization was increased. The drugs clinical development program had been completed before the guidance, but because of the new rule, the company launched savor timi 53. Regardless, the savortimi 53 trial met the primary safety objective demonstrating no increased risk of cardiovascular death, myocardial infarction, or. Saxagliptin and cancer in the savortimi 53 trial request pdf. Savortimi 53 demonstrated noninferiority for major cardiovascular events cardiovascular death, myocardial infarction, stroke but not superiority. Despite the development of new therapeutic strategies to improve glycemic control, recent clinical data from the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitusthrombolysis in myocardial infarction savortimi 53 study observed an unexpected finding of an excess of adjudicated heart failure. Efficacy and safety of saxagliptin in older participants in. Savor timi 53 was a doubleblind, placebocontrolled trial that randomized patients with type 2 diabetes to either saxagliptin or placebo while all other diet and lifestyle modifications, background antihyperglycemic therapies except incretinbased therapies, and cardiovascular therapies were left to the discretion of the treating provider. The saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus savorthrombolysis in myocardial infarction timi 53 trial randomized trial of 16 492 patients placebo, n 8212. We conducted the trial at 788 sites in 26 countries see the supplementary appendix, available with the full text of this article at.
Timi 53 trial randomized 16,492 patients with t2dm who were at risk for cv events to receive saxagliptin or placeboforamedianperiodof2years14. The savortimi 53 trial supports the overall cv safety of saxagliptin in a robust number of elderly and very elderly participants, although the risk of heart failure hospitalization was increased. Indeed, in the savortimi 53 trial, the decrease in albuminuria. Onglyza and kombiglyze xr diabetes drugs complications lawsuits. Bhatt and avivit cahn and boaz hirshberg and cheryl wei and kyungah im and aliza rozenberg and. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus savor timi 53 trial 1. This trial was designed to evaluate the safety and efficacy. Bergmark ba, bhatt dl, mcguire dk, cahn a, mosenzon o, steg pg, im k, kanevsky e, gurmu y, raz i, braunwald e, scirica bm. Oct 28, 2014 heart failure, saxagliptin, and diabetes mellitus. Design, setting, and participants the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitusthrombolysis in myocardial infarction savortimi 53 study was performed from may 2010 to may 20 and evaluated the safety of saxagliptin vs placebo in patients with type 2 diabetes with overt cardiovascular disease. Verify the role of initial combination therapy in patients.
Pdf heart failure, saxagliptin, and diabetes mellitus. Pdf saxagliptin and cardiovascular outcomes in patients with. The results of the savor timi 53 trial indicate that saxagliptin, a dpp4 inhibitor, is not associated with an excess of cv events as compared with placebo in patients with dm2 and either established cv disease or risk factors. Savortimi 53, a multicenter, randomized, doubleblind, placebocontrolled phase 4 trial conducted at 788 sites in 26 countries, included patients with type 2 diabetes mellitus, hba1c levels between 6. Saxagliptin and cardiovascular outcomes in patients with type. Does saxagliptin reduce the risk of cardiovascular events. The savor timi 53 trial and examine trial showed that the dpp4 inhibitors sitagliptin and alogliptin did not increase or decrease the risk of major adverse cv events. Metformin use and clinical outcomes among patients with. Saxagliptin and cardiovascular outcomes in patients with type 2. The saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitusthrombolysis in myocardial infarction savortimi 53 study was performed from may 2010 to may 20 and evaluated the safety of saxagliptin vs placebo in patients with type 2 diabetes with overt cardiovascular disease. However, few diabetes mellitus trials have prospectively evaluated and. The safety of dipeptidyl peptidase 4 inhibitors and the risk. Efficacy and safety of saxagliptin inolderparticipantsinthe savortimi 53 trial diabetes care 2015.
Bhatt, md, mphon behalf of the savortimi 53 steering committee and investigators. A posthoc analysis of the savortimi 53 trial showed that the dipeptidyl peptidase4 inhibitor saxagliptin was better than placebo in maintaining. The drugs clinical development program had been completed before the guidance, but because of the new rule, the company launched savortimi 53. Bhatt and avivit cahn and boaz hirshberg and cheryl wei and kyungah im and aliza rozenberg and ilan. Dapagliflozin effect on cardiovascular eventsthrombolysis in. Efficacy and safety of saxagliptin inolderparticipantsinthe. However, generalization of these results would be cautious in that the study comprised patients with relatively early stage of dkd. Incidence of fractures in patients with type 2 diabetes in. As described previously, 19 the savor timi 53 trial was a multicenter, randomized, doubleblind, placebocontrolled trial that randomized 16 492 patients at 788 sites in 26 countries from may 2010 to december 2011 with type 2 dm, hemoglobin a1c between 6.
Cardiovascular outcomes according to urinary albumin and kidney disease in patients with type 2 diabetes at high cardiovascular risk. Patients had type 2 diabetes with hba 1c between 6. Patients with t2dm at risk for cardiovascular events. Placebocontrolled phase iv trial saxagliptin 5mg daily or 2.
1341 966 299 226 991 1222 909 151 687 796 213 773 1244 1138 158 995 1036 18 768 1387 1376 601 121 1508 640 1325 1319 741 930 1497 1459 684 1264 1406 684 204 905 1088 208 180 1098 1219 100 1438